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a  b  s  t  r  a  c  t
The  hemocompatibility  of  nanoparticles  is  of critical  importance  for their  systemic  administration  as  drug
delivery  systems.  Formulations  of lipid-core  nanocapsules,  stabilized  with  polysorbate  80-lecithin  and
uncoated  or  coated  with  chitosan  (LNC  and  LNC-CS),  were  prepared  and  characterized  by  laser  diffraction
(D[4,3]:  129  and  134  nm),  dynamic  light  scattering  (119  nm  and  133  nm),  nanoparticle  tracking  (D50:  124
and  139  nm)  and  particle  mobility  (zeta  potential:  −15.1  mV  and  +9.3  mV)  analysis.  In vitro  hemocom-
patibility  studies  were  carried  out  with  mixtures  of  nanocapsule  suspensions  in human  blood  at  2% and
10%  (v/v).  The  prothrombin  time  showed  no  signiﬁcant  change  independently  of  the  nanocapsule  surface




pensions  at  2% (v/v)  in  plasma  did not  inﬂuence  the  clotting  time.  Even  though  suspensions  at  10%  (v/v)
in  plasma  decreased  the  clotting  times  (p  <  0.05),  the  values  were  within  the  normal  range.  The  ability  of
plasma  to activate  the  coagulation  system  was  maintained  after  the  addition  of the formulations.  Sus-
pensions  at 2% (v/v)  in  blood  showed  no signiﬁcant  hemolysis  or  platelet  aggregation.  In conclusion,  the
lipid-core  nanocapsules  uncoated  or  coated  with  chitosan  are  hemocompatible  representing  a potential
innovative  nanotechnological  formulation  for intravenous  administration.. Introduction
Currently, research involving nanoparticulate systems applied
o medicine has assumed a signiﬁcant role in the obtainment of
ew and/or enhanced diagnostic and therapeutic methods for use
n health promotion. In this context, most of these new technolo-
ies are intended for systemic use and thus their biocompatibility
s an important issue (Koziara et al., 2005; Cenni et al., 2008;
ichanetzis et al., 2008). Nanoparticles have been administered
y systemic route mainly as platforms or carries for otherwise
nsoluble or poorly soluble drugs, imaging agents and gene deliv-
ry purposes (Dobrovolskaia et al., 2009). Among the applications,
tudies involving nanoparticles as agents for drug delivery in can-
er therapy are highlighted (Byrne et al., 2008; Huynh et al., 2009).
he main beneﬁts of using nanoparticles as drug carriers include
he reduction of side effects and the improvement of efﬁcacy due
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to active or passive targeting of the carried drug to locations in the
body where it can be most effective (Dobrovolskaia et al., 2009).
Despite  the signiﬁcant scientiﬁc interest and promising poten-
tial, the safety of nanoparticulate systems remains a growing
concern considering that biological applications of nanoparti-
cles could lead to unpredictable effects (Nafee et al., 2009; Zern
et al., 2011). Ideal systems are those that prevent or delay pro-
tein adsorption onto the nanoparticle surface (opsonization), and
their subsequent uptake by macrophages, prolonging the circu-
lation time of the nanoparticles (Cai et al., 2009). Given their
nanoscale size, nanoparticles might have a low hemocompatibil-
ity in comparison with their starting bulk materials due to the
higher surface/volume ratio and the greater number of reactive
groups on the surface (Cenni et al., 2008). Nanoparticles should nei-
ther activate platelets, hemolysis, coagulation factors, or signaling
molecules for leukocytes nor induce damage to endothelial cells.
These events are related to the occurrence of thrombotic, hemor-
rhagic, hemolytic and inﬂammatory events (Koziara et al., 2005;
Open access under the Elsevier OA license.Mayer et al., 2009).
To  avoid these events, one of the main goals in nanomedicine is
to ﬁnd biocompatible and biodegradable materials to obtain
nanoparticulate systems. The most common choices are
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iodegradable and biocompatible polyesters such as poly(d,l-
actic acid) (PLA) (Jones and Grainger, 2009), poly(caprolactone)
PCL) (Cai et al., 2009) or poly(lactide-co-glycolide) (PLGA) (Nafee
t al., 2009). Polymeric nanoparticles may  also be coated with
ydrophilic polymers, such as poly(ethylene glycol) (PEG) and
ethoxy poly(ethylene glycol), to reduce adsorption of the plasma
roteins such as opsonins and apolipoproteins on their surface
Letchford et al., 2009; Byrne et al., 2008).
Similarly, polysorbate 80 [poly(oxyethylene)-sorbitan-20-
onooleate] can be used to delay opsonization. Lipid-core
anocapsules stabilized with polysorbate 80 showed efﬁcient
elivery of drugs to the brain (Frozza et al., 2010) and to inﬂamed
issues (Bernardi et al., 2009). Furthermore, attempts have been
ade to modify the surface of PCL or PLGA nanoparticles using
ationic polymers, such as chitosan (Cai et al., 2009; Nafee et al.,
009). Chitosan is a cationic polysaccharide with biocompatible
nd nontoxic properties making this polymer a good candidate for
harmaceutical applications (Oyarzun-Ampuero et al., 2010; Xu
t al., 2010). Its hydrophilic nature and the presence of primary
mine groups enable the association of delicate compounds such as
eptides and proteins (Aktas et al., 2005; Baldrick, 2010). Chitosan
anoparticles have been used for widespread applications such as
rug delivery, muco-adhesive dosage forms, rapid release forms,
mproved peptide delivery, colonic drug delivery and gene delivery
Cui and Mumper, 2001; Aktas et al., 2005; Wang et al., 2011). In
ddition, the use of chitosan-based nanoparticles as a nanoscale
accine delivery system for subunit antigens has been proposed
Prego et al., 2010) as a new system for hepatitis B immunization.
Nanoparticles with cationic shells have been found to be toxic
nd it has been suggested that this toxicity is due to charge interac-
ions with the plasma membrane and/or with negatively-charged
ell components and proteins (Skotak et al., 2008; Nafee et al., 2009;
aldrick, 2010). On the other hand, negatively-charged nanoparti-
les can induce platelet aggregation to a greater extent than cationic
r neutral nanoparticles (Koziara et al., 2005). Moreover, the abil-
ty of the nanoparticles to inhibit platelet aggregation is dependent
n their particle size, as well as surface hydrophobicity and charge
Koziara et al., 2005; Xu et al., 2010).
Lipid-core nanocapsules, which are non-ionic carriers, have
hown great potential as drug delivery systems for topical, oral
r systemic applications (Alves et al., 2007; Cattani et al., 2010;
ruz et al., 2006; Bernardi et al., 2009; Frozza et al., 2010).
he supramolecular structure of these new carriers has been
ully investigated demonstrating that the core is composed of a
ispersion of oil and sorbitan monostearate surrounded by the
oly(-caprolactone) wall and stabilized by polysorbate 80 (Cruz
t al., 2006; Jager et al., 2007, 2009).
Taking all of the above considerations into account, the objec-
ive of our study was to develop modiﬁed lipid-core nanocapsules
y stabilizing them simultaneously with polysorbate 80 and
ecithin to generate negatively-charged lipid-core nanocapsules,
ollowed by coating with chitosan to obtain positively-charged
ipid-core nanocapsules. Furthermore, we aimed to determine the
emocompatibility of both negatively and positively-charged for-
ulations, herein referred to as LNC and LNC-CS, by evaluating their
n vitro hemocompatibility with special focus on hemolytic activity,
latelet function, membrane integrity, and blood coagulation.
. Material and methods
.1. MaterialsPoly(-caprolactone) (PCL) (,-dihydroxy functional poly-
er; Mn  10,000 g mol−1, Mw 14,000 g mol−1), low molar weight
hitosan (Mw  50,000–190,000 g mol−1, 75–85% deacetylated poly-
er), sorbitan monostearate (Span 60®) and Triton X-100 werePharmaceutics 426 (2012) 271– 279
supplied by Sigma–Aldrich (U.S.). Lipoid S75 (soybean lecithin) was
obtained from Lipoid (Germany). Caprylic/capric triglyceride and
polysorbate 80 were purchased from Delaware (Brazil). Reagent
kits to measure prothrombin time (PT) and activated partial
thromboplastin time (APTT), for hemoglobin analysis and for the
determination of the activity of enzyme lactate dehydrogenase
(LDH) and commercial standard serum (Qualitrol 1H) were pur-
chased from Labtest Diagnóstica (Brazil). All aqueous solutions
were prepared with deionized water (DI) using a Millipore Direct-
Q system with a resistivity of 18.2 M. The solvents, acetone and
ethanol PA, were obtained from Nuclear (Brazil). PBS buffer (pH
7.2), May–Grünwald and Giemsa stains, EDTA K2 and sodium citrate
anticoagulants were obtained from Laborclin (Brazil). All reagents
were used as received.
2.2. Preparation of lipid-core nanocapsule aqueous suspensions
A formulation of lipid-core nanocapsules stabilized with
polysorbate 80 and lecithin was prepared using a methodology
previously reported for lipid-core nanocapsules stabilized with
polysorbate 80 (Jager et al., 2009). The methodology is based on the
principle of interfacial deposition of pre-formed polymers reported
for polymeric nanocapsules (Fessi et al., 1989).
The procedure consisted of an organic phase containing PCL
(0.1 g), sorbitan monostearate (0.04 g), and caprylic/capric triglyc-
eride (0.12 g) dissolved in acetone (25 mL). In parallel, an ethanolic
solution (5 mL)  containing lecithin (0.03 g) was prepared and
poured into the organic phase. This mixture was then poured into
an aqueous solution (50 mL)  containing polysorbate 80 (0.08 g)
under moderate magnetic stirring at 40 ◦C. After 10 min, the mix-
ture was  evaporated under reduced pressure to eliminate the
acetone and to concentrate the suspension (near 9 mL). The ﬁnal
volume was  adjusted in a volumetric ﬂask to 10 mL. This formula-
tion was called LNC.
To coat the lipid-core nanocapsules, a 0.3% (w/v) chitosan solu-
tion was  prepared by dissolving the polysaccharide in 10 mL  of
1% acetic acid aqueous solution. This solution (1 mL) was  slowly
added to 9 mL  of LNC suspension under moderate magnetic stir-
ring. The reaction medium remained under stirring for 4 h at room
temperature. This formulation was  called LNC-CS.
2.3. Physico-chemical characterization
2.3.1. Zeta potential
Zeta potential () was  determined on a ZetaSizer Nano ZS
(Malvern Instruments Ltd., UK). This equipment operates in the
range of 3.8 nm to 100 m.  Measurements were taken at 25 ◦C. The
samples were diluted (500×) in 10 mmol  L−1 NaCl aqueous solu-
tion. To avoid any sample selection the formulations were added
into pre-ﬁltered medium without treatment (centrifugation or ﬁl-
tration). All samples were analyzed in triplicate batches (n = 3).
2.3.2. pH measurements
The pH of the lipid-core nanocapsule suspensions was  measured
without previous dilution using a calibrated potentiometer B474
(Micronal, Brazil) at 25 ◦C. All samples were analyzed in triplicate
batches (n = 3).
2.3.3. Granulometric proﬁles and mean diameters by laser
diffraction
The size distribution proﬁles were determined by laser diffrac-
tion using a Mastersizer 2000 (Malvern Instruments Ltd., UK).
This equipment measures materials in the range of 0.02–2000 m.
Each sample was directly inserted into the wet sample dispersion
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escribed as volume-weighted mean diameters (D4,3). All samples
ere analyzed in triplicate batches (n = 3).
.3.4. Particle sizing by dynamic light scattering
The formulations were also characterized by dynamic light scat-
ering (DLS) using a ZetaSizer Nano ZS (Malvern Instruments Ltd.,
K). This equipment operates in a working size range of 0.3 nm
o 10.0 m.  The measurements were taken at 25 ◦C. The average
iameters were determined after diluting the samples (500×) in
ltrapure water. To avoid any sample selection the formulations
ere added into pre-ﬁltered medium without treatment (centrifu-
ation or ﬁltration). All samples were analyzed in triplicate batches
n = 3).
.3.5. Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) is a method of visualizing
nd analyzing particles in liquid dispersions (NanoSight LM10 &
TA 2.0 Analytical Software, NanoSight Ltd.). This technique mea-
ures particles in the range of 10–1000 nm.  NTA is carried out
sing a small amount of the diluted samples (0.5 mL)  introduced
nto the chamber by a syringe. The chamber is placed on an opti-
al microscope and the particles are illuminated by a laser diode
635 nm wavelength). The video images of the Brownian motion of
he individual particles are followed in real-time via CCD camera
nd analyzed using the NTA 2.0 Analytical Software (NanoSight®).
The light scattered by the particles is captured by a digital cam-
ra and the motion of each particle is tracked from frame to frame.
he rate of particle movement is related to a sphere equivalent
ydrodynamic radius as calculated using the Stokes–Einstein equa-
ion. The particle size distributions are calculated on a particle by
article basis. Visible particles in the frame correspond to each sep-
rate light scattering center which is seen as an individual particle
uring ﬁlming (Filipe et al., 2010).
The formulations were diluted 5000 times using ultrapure water
MillQ®) and each video clip was captured over 120 s. The auto-
atic detection threshold was enabled and the maximum particle
ump was set at 10 in the NTA software. All measurements were
erformed in triplicate batches. The polydispersity of the particle
izes was calculated as Span, which is the width of the distribution
ased on the 10%, 50% and 90% of the cumulative distribution of
izes.
.3.6. Multiple light scattering
To check the colloidal physical stability, the lipid-core nanocap-
ule suspensions were evaluated by multiple light scattering using
 Turbiscan LAb (Formulaction, France). In this method the light
ource is an electro luminescent diode in the near infrared (880 nm
avelength) and two synchronous optical sensors receive, respec-
ively, the light transmitted through the sample (0◦ from the
ncident light, transmission sensor), and the light backscattered by
he sample (135◦ from the incident radiation, backscattering detec-
or), acquiring transmission and backscattering data every 40 m
rom the bottom to the top of the cell (Mengual et al., 1999). The
amples (10 mL)  were poured into the glass cells without any treat-
ent or dilution and analyzed at 25 ◦C for 1 h using the scan mode.
.4. Blood compatibility
.4.1. Blood and plasma samples
Whole blood was collected from a healthy human volunteer in
n evacuated siliconized glass tube containing 3.2% sodium citrate
r EDTA as anticoagulants. All blood samples were obtained from
he Faculdade de Farmácia at the Universidade Federal do Rio Grande
o Sul (Brazil). As the stages of blood collection and centrifugation
re critical to the platelet activation status, the blood samples were
btained without tourniquet. Ethical approval for this study wasPharmaceutics 426 (2012) 271– 279 273
granted by the Human Ethics Committee of the Universidade Federal
do Rio Grande do Sul,  Brazil (protocol # 19404, UFRGS).
2.4.2. Plasma clotting
Platelet-poor plasma was prepared by centrifugation of freshly
drawn whole blood for 10 min, at 1344 × g and either used fresh or
stored at −20 ◦C. The APTT and PT were determined by the appear-
ance of a macroscopic clot which indicated the end of the reaction.
Lipid-core nanocapsule suspensions (LNC and LNC-CS) were added
to the plasma samples at 2 and 10% (v/v) and stirred for 1 h at
37 ◦C. For the PT determination, PT Hemostasis reagent (Labtest®)
was added to the sample, whereas for APTT partial thromboplastin
reagent (Labtest®) was added along with calcium chloride. Nor-
mal  controls consisted of equivalent volumes of PBS added to the
plasma at the same concentrations used for the nanocapsule sus-
pensions. All experiments were performed at 37 ◦C and in triplicate
batches (n = 3).
2.4.3. Hemolysis
Hemolysis induced by particle treatment was  assessed photo-
metrically with a colorimetric endpoint hemoglobin reagent kit
(Labtest®). Whole blood was collected in an evacuated siliconized
glass tube containing EDTA as an anticoagulant and the number of
erythrocytes present (4.76 ×106 cells L−1) was determined using
an automated hematology counter (ABX Micros 60, Horiba-ABX,
France). Formulations (LNC and LNC-CS) were incubated at 2 and
10% (v/v) with the whole blood at 37 ◦C. A spontaneous hemolysis
control was  prepared by incubating erythrocytes with PBS, also at
2 and 10% (v/v). A 100% hemolysis control was prepared by incu-
bating erythrocytes with an equal volume of Triton X-100 (1%).
As the internal quality control, we  used a commercial standard of
hemoglobin produced by the manufacturer of the hemoglobin kit.
All tubes were incubated at 37 ◦C with tumbling. At time intervals
of 1, 2, 4 and 8 h the tubes were centrifuged at 1344 × g for 10 min
and the hemoglobin released into the supernatant was detected at
540 nm (UV-Vis 1601 PC Spectrophotometer, Schimadzu, Japan).
The percentage of hemolysis was calculated for each sample (Eq.
(1)).
%Hemolysis = Abssample − Absspontaneous
Abs100% hemolysis
× 100 (1)
where Abssample is the absorbance of the supernatant of erythro-
cytes incubated with nanoparticle suspension, Absspontaneous is the
absorbance of the supernatant of erythrocytes incubated with PBS
suspension and, ﬁnally, Abs100% hemolysis is the absorbance of the
supernatant of the erythrocyte incubated with Triton X-100 (1%)
solution in PBS suspension. All sample were analyzed in triplicate
batches (n = 3).
2.4.4. Evaluation of the erythrocyte membrane integrity
The activity of the enzyme LDH released from erythrocytes by
particle treatment was assessed photometrically using the LDH
commercial kit (Labtest®). Firstly, for the removal of plasma and
leukocytes, the erythrocyte concentrate was  centrifuged for 10 min,
at 1344 × g and room temperature. The peripheral blood mononu-
clear cells and plasma band were drawn with a Pasteur pipette.
The pellet consisting of erythrocytes was washed three times with
PBS. A 20% suspension of erythrocytes (9.52 × 105 cells L−1 deter-
mined by ABX Micros 60, Horiba-ABX, France) in PBS was  used
for the experiments. Lipid-core nanocapsule suspensions (LNC and
LNC-CS) were incubated at 2 and 10% (v/v) with the erythrocyte
suspension at 37 ◦C. A spontaneous LDH control was  prepared by
incubation of the erythrocyte suspension with PBS, also at 2 and
10% (v/v). A 100% LDH control was  prepared by the addition of an
equal volume of erythrocyte suspension and Triton X-100 (1%). As
the internal quality control, we  used a commercial standard serum
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Qualitrol 1H – Labtest®). All tubes were incubated at 37 ◦C and
tirred for 1 h. After that, the tubes were centrifuged at 1344 × g
or 10 min  and the LDH released in the supernatant was  detected
t 500 nm (UV-Vis 1601 PC Spectrophotometer, Schimadzu, Japan).
he concentration of LDH released was calculated through Eq. (2).
actate dehydrogenase(U L−1) = Abssample − Abscontrol
Absst
× 150 (2)
here Abssample is the absorbance of the supernatant of the ery-
hrocyte with nanoparticle suspension, Abscontrol is the absorbance
f the supernatant of the erythrocyte without nanoparticle sus-
ension added in the substrate reaction and ﬁnally, Absst is the
bsorbance of the supernatant of the erythrocyte with LDH stan-
ard (150 U L−1, according to the manufacturer). All samples were
nalyzed in triplicate batches (n = 3).
.4.5. Platelet aggregation tests
To identify platelet changes due to the particle treatment,
eripheral blood smears were ﬁrstly prepared after the incubation
f citrated whole blood with lipid-core nanocapsules. In brief, the
amples were incubated with whole blood at 2 and 10% (v/v) for
0 min  at 37 ◦C with gentle agitation (400 rpm). Likewise, in the
ame ratio, equal volumes of whole blood and PBS were incubated
nd served as the control of spontaneous platelet aggregation.
After incubation peripheral blood smears were stained, ﬁrstly
or 3 min  with May–Grünwald staining and secondly with Giensa
taining for 15 min  (Bioclin, Brazil). After rinsing in water the dried
mears were analyzed with an optical microscope (Primo Star,
eiss, Germany) in immersion objective and images were collected
sing the digital system (Canon PC 1250 and Soligor adapter tube
or Canon A 650 IS B52 wide, Japan).
In a second step we evaluated platelet aggregation in citrated
hole blood samples before and after addition of LNC and LNC-CS
t 2 and 10% (v/v). The citrated whole blood containing nanoparticle
uspensions remained under gentle agitation (400 rpm) for 30 min
t 37 ◦C before analysis. We  used a hematological counter (ABX
icros 60, Horiba-ABX, France) that determined by laser diffraction
he platelet count and established the mean platelet volume (MPV).
ll samples were analyzed in triplicate batches (n = 3).
.5. Statistical analysis
All results are expressed as the mean value ± the standard devi-
tion of the mean and were statistically analyzed using analysis
f variance (ANOVA). Results presenting p < 0.05 were considered
tatistically different. The comparisons among the averages were
erformed using Tukey’s test.
. Results and discussion
.1. Preparation of lipid-core nanocapsules
Negatively-charged lipid-core nanocapsules (LNC) were pre-
ared by interfacial deposition of polymer using sorbitan
onostearate and caprilic/capric triglyceride as the lipid dispersion
n the core, poly(-caprolactone) as the polymer wall, and polysor-
ate 80 and lecithin as stabilizers. Chitosan was used as the coating
aterial for a second formulation in order to evaluate the inﬂu-
nce of the surface charge on the hemocompatibility properties
f the lipid-core nanocapsules. In this case, chitosan-coated lipid
ore nanocapsules (LNC-CS) were obtained after adding a chitosan
olution to a sample of LNC. Both formulations had a white-bluish
palescent aspect with the Tyndall effect.
The LNC showed a negative zeta potential of −15.1 ± 1.0 mV,
hile LNC-CS had a positive value of +9.3 ± 2.5 mV. The zeta poten-
ial determined for LNC is slightly more negative than the valuePharmaceutics 426 (2012) 271– 279
observed for lipid-core nanocapsules prepared without lecithin
(−9.4 ± 0.7 mV)  (Jager et al., 2009). According to the literature
(Mosqueira et al., 2000), the presence of phosphatidic acid, as an
impurity in lecithin, is responsible for the negative charge on the
particle surface. The positive zeta potential value observed for LNC-
CS indicated that chitosan is located at the particle–water interface,
externally coating the lipid-core nanocapsules.
The lipid-core nanocapsule suspensions showed pH values of
5.2 ± 0.1 for LNC and 3.8 ± 0.2 for LNC-CS. The more pronounced
acidity after coating with chitosan is a consequence of the 1% acetic
acid aqueous solution used to dissolve the polysaccharide.
3.2. Granulometry and particle sizing
The laser diffraction technique was used to determine the gran-
ulometric proﬁles of the formulations. Since the suspensions are
directly inserted into the sample dispersing unit this analysis is
able to determine the purity of the submicrometric population and
their size distribution proﬁles demonstrating the homogeneity of
the nanoparticle population.
The granulometric proﬁles (by volume) showed unimodal size
distributions for LNC and LNC-CS suspensions (Fig. 1A and C). The
volume-weighted mean diameters (D4.3) were 129 nm (LNC) and
134 nm (LNC-CS). The results indicated that no microscopic con-
tamination is present in the formulations. It is noteworthy that the
measurements were carried out by placing each sample directly
into the wet  sample dispersion unit without previous treatment
(ﬁltration or centrifugation). Thus, the preparation process pro-
duced quantitative yields of particles in the submicrometric range.
Furthermore, the LNC coating did not cause any precipitation or
agglomeration. Besides a slight broadening of the size distribu-
tions, the lipid-core nanocapsules maintained their nanometric
sizes after coating with chitosan.
Moreover, the size distributions plotted by number (Fig. 1B and
D) showed almost superposed proﬁles compared to the distribu-
tions by volume (Fig. 1A and C). The results indicated that both
formulations present high homogeneity of nanoscopic populations,
and veriﬁed narrow size distributions for both colloidal suspen-
sions (LNC and LNC-CS).
LNC and LNC-CS were considered suitable formulations for
follow-up studies, since they are composed of self-assembled bio-
compatible materials presenting particle sizes lower than 500 nm.
These characteristics are of great importance when parenteral
administration is the goal for therapeutic applications.
To characterize the hydrodynamic diameters of the LNC and
LNC-CS suspensions, DLS and NTA were performed. The DLS
analysis indicated that the particles had z-average diameters of
119 ± 1.71 nm and 133 ± 1.72 nm and polydispersity indexes lower
than 0.17 (Table 1). The size distribution proﬁles showed unimodal
populations by intensity, volume or number (data not shown). The
data indicated a high degree of homogeneity in the particle size of
the nanometric population in each sample.
Considering the NTA analysis, Brownian motion of the nanocap-
sules in suspension was  observed by registering the light scattered.
Well dispersed and spatially resolved particles were visualized in
the frame images obtained from the random motion of the particles
in suspension captured using a CCD camera for LNC (temperature
22.8 ◦C and viscosity 0.94 cP) and LNC-CS (temperature 22.6 ◦C and
viscosity 0.94 cP). These images show a microscopic view of the
scattering particles illuminated by the laser diode. Larger particles
scatter more light and larger luminous dots appeared in the video
frame, while smaller particles move faster and longer distances
with respect to larger ones (Jakubowicz, 2008; Gallego-Urrea et al.,
2009). Even though different intensities of light scattering can be
observed for each formulation, cumulative data obtained for the
percentile of the particle distribution by NTA showed diameters in

































dFig. 1. Granulometric proﬁles obtained by laser diffraction for LNC (A and B) and 
 narrow size distribution (Table 1). Furthermore, the polydisper-
ity (Span) was lower than 1 (0.72 for LNC and 0.78 for LNC-CS)
onﬁrming the homogeneity and narrow size distribution of the
NC and LNC-CS. The different proportions of dilution for the DLS
nd NTA analyses did not inﬂuence the particle mean size.
Comparing DLS and NTA, similar sizes of particles for LNC
nd LNC-CS were determined. Thus, the data indicate that LNC
ere obtained in a narrow size distribution without the need
or puriﬁcation to yield exclusively one population of nanoscopic
articles. In addition, the coating with chitosan did not modify
he aggregation state of the LNC and did not cause agglomera-
ion or precipitation in the suspension. Furthermore, LNC-CS had
n average particle size 15 nm greater than LNC (Table 1). This
hange in the mean particle size observed after coating with chi-
osan and the inversion of the zeta potential maintaining a single
opulation of particles, conﬁrmed the high quality, homogene-
ty and reproducibility in obtaining and coating the lipid-core
anocapsules.
.3. Physical stability determined by multiple light scattering
Multiple light scattering analysis by Turbiscan® can be used
o determine reversible (creaming and sedimentation) and irre-
ersible (coalescence and segregation) destabilization phenomena
irectly in the formulation without any prior dilution or treatment
ore easily than other techniques (Celia et al., 2009). LNC and
NC-CS are opaque and no transmission was detected by multiple
ight scattering analysis. Thus, variations in backscattering were
nalyzed.
Negative variations in the relative backscattering at the top of
he cells were observed (−2% for LNC and −3% for LNC-CS). The
mall values determined during the experimental period indicated
low sedimentation. No variation at the middle of the cell was
bserved indicating the absence of ﬂocculation or coalescence. LNC
able 1
verage particle size and polydispersity index (PDI) determined by dynamic light scatterin
istribution proﬁle, and mean size determined by nanoparticle tracking analysis (NTA) fo
Sample Dynamic light scattering (DLS) N
z-Average diameter (nm) PDI C
D
LNC 119 ± 1.71 0.10 ± 0.01 8
LNC-CS  133 ± 1.12 0.17 ± 0.02 9S (C and D). Parameters demonstrated by volume and number of particles (n = 3).
and LNC-CS presented density higher than the external phase as
expected considering the density of the raw materials.
3.4. Blood hemocompatibility
3.4.1. Plasma clotting
The compatibility of the LNC and LNC-CS samples with human
blood was  evaluated by investigating their ability to alter the coagu-
lation times and cause hemolysis. Coagulation of human blood was
assessed in the presence of either LNC or LNC-CS suspensions at
2 and 10% (v/v) in citrated plasma samples (Fig. 2). The concentra-
tions of lipid-core nanocapsule suspensions in plasma were chosen
based on an acceptable volume for i.v. bolus administration (lower
concentration, 2%, v/v) and on a large excess (higher concentration,
10%, v/v).
The blood coagulation cascade included intrinsic, extrinsic and
common pathways. APTT and PT are mainly used to examine the
intrinsic and extrinsic pathways, respectively (Letchford et al.,
2009; Xu et al., 2010). In PT analysis, LNC (13.7 ± 0.3 s) and LNC-
CS (14.4 ± 0.7 s), both at 2% (v/v) in plasma, caused no statistical
difference in the clotting times compared to the 2% PBS control
(12.9 ± 0.8 s). However, these formulations caused a signiﬁcant
increase in the clotting time compared to the 10% (v/v) PBS con-
trol group (13 ± 0.5 s) when the amount of suspension added to
the plasma was  10% (v/v) (LNC 15 ± 0.8 s and LNC-CS 15.1 ± 1 s)
(p < 0.05) (Fig. 2A).
The effects on the extrinsic pathway of blood coagulation are
better evaluated when the measurement of time until ﬁbrin clot
formation are standardized in terms of percentage of prothrombin
activity. At 2% (v/v) in the plasma, LNC and LNC-CS showed high
prothrombin activity: 88% and 81%, respectively. Lower values for
prothrombin activity were observed when the amount of suspen-
sion added to the plasma was  10% (v/v) (76% for LNC and 73% for
LNC-CS). These results indicated that LNC and LNC-CS suspensions
g (DLS), D10, D50 and D90 diameters based on 10%, 50% and 90% of the cumulative
r LNC and LNC-CS suspensions (n = 3).
anoparticle tracking analysis (NTA)
umulative data Mean (nm)
10 (nm) D50 (nm) D90 (nm)
5 124 174 128 ± 35
4 139 202 145 ± 46
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of hemolytic events when administered intravenously. In order
to preserve the integrity and functionality of erythrocytes in
whole blood samples, the limits prescribed by Brazilian law andig. 2. Effect of lipid-core nanocapsules on the (A) prothrombin time (PT) and (B) 
v/v)  were compared to PBS controls. All bars represent mean clotting time ± SD (n 
dded at 2% (v/v) to the plasma did not inﬂuence the extrinsic path-
ay of blood coagulation maintaining the in vitro anticoagulation
ctivity. Furthermore, even though a high concentration of lipid-
ore nanocapsules is added (10%, v/v) prothrombin activity levels
re in a range greater that 70% (Cenni et al., 2008; von Ahsen et al.,
000).
Considering the intrinsic pathway of the blood coagulation cas-
ade, the coagulation times obtained for the APTT analysis showed
hat LNC (39.9 ± 1.7 s) and LNC-CS (41.4 ± 1.2 s) suspensions at 2%
v/v) in plasma did not inﬂuence the clotting time compared to
he 2% PBS (v/v) control (40 ± 0.8 s). However, when these lipid-
ore nanocapsule suspensions were added at 10% (v/v) in plasma,
igniﬁcant decreases in the clotting times were observed for LNC
33.5 ± 1.2 s) and LNC-CS (37.9 ± 1.2 s) compared to the 10% PBS
v/v) control (41 ± 1.7 s) (p < 0.05) (Fig. 2B). The reference ranges
ary depending on the type of population studied; however, for
uidance purposes, some authors report that the time until clot
ormation is usually between 32 and 46 s (Letchford et al., 2009). In
his case, the decreases in plasma clotting times observed for LNC
nd LNC-CS at 10% (v/v) in plasma were considered to be of minor
oncern as the experimental values were within the normal range.
The results demonstrated that the ability of plasma samples to
ctivate the coagulation system was maintained after the addition
f lipid-core nanocapsule suspensions. Even using a concentration
f 10% (v/v) of lipid-core nanocapsule suspensions in plasma, there
as no impairment of the anticoagulant ability via the extrinsic
r intrinsic pathway. Moreover, plasma coagulation factors were
reserved in the presence of both formulations. At higher concen-
rations, the number of nanocapsules is high and the adsorption
f coagulation factors could cause their deﬁciency in plasma pro-
oting an increase in the time until the formation of a ﬁbrin clot.
oreover, the coagulation proﬁles for LNC or LNC-CS (p > 0.05) didted partial thromboplastin time (APTT). LNC and LNC-CS in plasma at 2% and 10%
 < 0.05, different from control.
not differ when 10% (v/v) of nanocapsule suspension was added to
the plasma.
3.4.2. Hemolysis
Another important feature in the development of nanopar-
ticulate systems for parenteral administration is to determine
their ability to cause hemolysis. Therefore, LNC and LNC-CS were
evaluated for their ability to cause lysis in human erythrocytes
(Fig. 3). Nanoparticulate systems should not favor the formationFig. 3. Hemolysis assessed by release of hemoglobin in whole blood samples after
the addition of LNC and LNC-CS suspensions to blood at 2% and 10% (v/v). All points
represent mean hemolysis time ± SD (n = 3).















































induced by both LNC and LNC-CS. In this case, the results indicatedig. 4. Erythrocyte lactate dehydrogenase release (LDH) after treatment with LNC a
epresent mean LDH release ± SD (n = 3). *p < 0.05, different from control.
nternational standards is 1% for spontaneous hemolysis (Hogman
t al., 1981; Brazil, 2010).
In this study, the values of hemolysis remained restricted to the
imits recommended when the whole blood was incubated with
ither LNC or LNC-CS suspensions at 2% (v/v) for 1, 2, 4 and 8 h of
ncubation. On the other hand, when the suspensions were added to
lood at 10% (v/v), with the same period of incubation, hemoglobin
as readily released into the extracellular environment, reaching
he average rate of 8% at the end of 8 h of incubation. This result
ould be explained either by a shift in polysorbate 80 from the col-
oids to the cells or by the interaction of chitosan with the cells
ue to the high concentration used (10%, v/v) causing the hemol-
sis. As previously described, surfactant molecules can penetrate
nd saturate the membrane causing solubilization of the lipids and
roteins (Jones, 1999; Letchford et al., 2009); and cationic polymers
an cause injury to erythrocytes due to electrostatic interactions
Nafee et al., 2009). Thus, the high speciﬁc surface area of the col-
oids, when LNC and LNC-CS suspensions were added to blood at
0% (v/v), could explain the injury to the erythrocyte membrane.
.4.3. Evaluation of the erythrocyte membrane integrity
The evaluation of the membrane integrity was also assessed by
uantifying the enzyme LDH (Fig. 4). In this experiment the leuko-
ytes and plasma were removed and only red blood cells in PBS
ere used to quantify the enzyme. This allowed the quantiﬁca-
ion of the erythrocyte LDH released and the evaluation of possible
isturbances in membrane integrity.
LNC and LNC-CS at 2% (v/v) in blood did not cause a signiﬁcant
ncrease in erythrocyte LDH release when compared to the sponta-
eous release observed using PBS in the cell suspension after 30 min
f incubation. The results indicated the maintenance of the mem-
rane integrity in the presence of either LNC or LNC-CS at 2% (v/v)
n blood. Thus, this reinforces the hypothesis that blood contain-
ng these lipid-core nanocapsules at this concentration may  not
amage the erythrocyte membrane to the point of releasing the
emoglobin component (complete rupture). Furthermore, the ery-
hrocytes maintained their permeability, observed by assessing the
DH release. On the other hand, when LNC or LNC-CS were added
o blood at 10% (v/v), signiﬁcant levels of damage to the mem-
rane were observed (p < 0.05). This result corroborates those of
he hemolysis experiment described above.
Comparing the differences between the negatively and
ositively-charged (i.e., uncoated and coated) lipid-core nanocap-
ules when added to blood at a concentration of 10% (v/v), the
ighest LDH release was observed for LNC-CS. This result is con-
istent with other studies in which cationic particles or polymers
aused greater adverse effects on blood cells and coagulation,
ithout necessarily affecting all cellular function (Vermette and
eagher, 2003; Jones and Grainger, 2009). Moreover, the presenceC-CS suspensions. Triton X-100 (1%) was considered 100% of cell damage. All bars
of a cationic polymer may  not necessarily imply extensive mem-
brane rupture and loss of hemoglobin components, but it is
sufﬁcient to cause an initial destabilization of the erythrocyte
membrane and thus facilitate the release of the LDH enzyme from
cells.
3.4.4. Platelets aggregation tests
The possibility of causing platelet aggregation by adding the
lipid-core nanocapsule suspensions to the whole blood was stud-
ied by visualizing platelets in the blood samples by light microscopy
and through the platelet count. To determine spontaneous aggre-
gation PBS was used as the control. To this aim, peripheral blood
smears were obtained using citrated whole blood incubated for
30 min  in the presence of PBS (as the control) or in the pres-
ence of the nanocapsule suspensions [LNC or LNC-CS at 2 and 10%
(v/v)] (Fig. 5). Erythrocytes, leucocytes and platelets were observed
and the platelets are indicated on the microphotographs. The
platelets were distributed evenly throughout in peripheral blood
smears prepared with 2% (v/v) of nanocapsule suspensions in blood.
Considering the light microscopy results, lipid-core nanocapsule
suspensions added to blood at 2% (v/v) had little inﬂuence on
the formation of platelet aggregates. On the other hand, small
agglomerates could be visualized when lipid-core nanocapsule sus-
pensions were added to blood at 10% (v/v) independently of their
coating (LNC or LNC-CS).
As the platelets visualization by light microscopy have limited
sensitivity in the evaluation of platelet aggregation, we  performed
additional analysis with a hematological counter. This method was
carried out to evaluated platelet concentration and MPV  (Fig. 6).
The platelet concentration determined for whole blood and whole
blood with PBS added at 2% (v/v) was maintained after adding
LNC and LNC-CS suspensions to blood at 2% (v/v) (p > 0.05). MPV
measurements corroborated these ﬁndings, since LNC or LNC-CS
suspensions in the blood at 2% (v/v) did not show variations in this
parameter (p > 0.05).
On the other hand, a decrease in the platelet concentration
compared to the PBS solution was  detected when LNC or LNC-CS
suspensions were added to the blood at 10% (v/v) (p < 0.05). The
results suggested that the lower number of platelets was  a con-
sequence of platelet aggregation since aggregates are counted as
single particles. This is most evident when the MPV  parameters
were increased after adding LNC or LNC-CS suspensions to blood
at 10% (v/v) (p < 0.05). The increase in the MPV  associated with the
lower number of platelets indicated signiﬁcant platelet aggregationthat the platelet aggregation was  inﬂuenced by the increase in the
speciﬁc surface area due to the addition of a higher volume fraction
of the formulations in the blood samples and probably not to the
chemical nature of the particle/water interface.
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Fig. 5. Light microscopy: smears were made of human blood stimulated with (A) 2% LNC, (B) 10% LNC, (C) 2% LNC-CS, (D) 10% LNC-CS and (E) PBS as the control. Arrows







sig. 6. Number of platelets and mean platelet volume (MPV) levels after adding the 
ean  ± SD (n = 3).
. Conclusions
Modiﬁed lipid-core nanocapsules were effectively obtained
ith negatively-charged (polysorbate 80-lecithin) and positively-
harged (chitosan) surfaces. The hemocompatibility study carried
ut with the negatively and positively-charged lipid-core nanocap-
ule suspensions (LNC and LNC-CS) investigated at two  differentr LNC-CS suspensions to citrated whole blood at 2% and 10% (v/v). All bars represent
concentrations in human blood (2 and 10%, v/v) showed very
promising results indicating good potential for their use in par-
enteral administration. Hence, regarding the activated partial
thromboplastin time, neither of the suspensions when added to
plasma at 2% (v/v) inﬂuenced the clotting time.
Furthermore, LNC and LNC-CS suspensions added to blood at
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ndicating their compatibility independently of the chemical
ature of their surface. Hemolysis and platelet aggregation
bserved for the suspensions added to blood at high concentration
10%, v/v) indicated that the speciﬁc surface area of the colloids
nﬂuenced the results more than the chemical nature of the
article/water interface. Taking all data obtained into account we
an infer that these lipid-core nanocapsules are potential sys-
ems for intravenous administration representing an innovative
anotechnological platform.
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